Immune function during GH treatment in GH-deficient adults: an 18-month randomized, placebo-controlled, double-blinded trial

TY - JOUR

T1 - Immune function during GH treatment in GH-deficient adults

T2 - an 18-month randomized, placebo-controlled, double-blinded trial

AU - Sneppen, S B

AU - Mersebach, H

AU - Ullum, H

AU - Feldt-Rasmussen, U

PY - 2002/12

Y1 - 2002/12

N2 - OBJECTIVE: The aim of the present study was to investigate natural killer (NK) cell function and lymphocyte subsets in GH-deficient (GHD) adults, before and during long-term GH treatment.STUDY DESIGN: We investigated immune function in 19 adults with severe GHD, before and during 18 months of randomized treatment with GH or placebo. Measurement of lymphocyte subsets and NK cell activity was performed. Data obtained from 110 healthy adults served as reference values.RESULTS: NK cell activity, both unstimulated and stimulated by interferon-a or interleukin-2, was significantly impaired in GHD patients. Similarly, NK cell concentration and the proportion of NK cells (CD16+) were reduced in GHD patients compared to controls. Both total and proportional CD4 + cells were increased in patients compared with controls. IGF-I increased significantly during treatment, but the immune functions investigated were unaltered.CONCLUSIONS: GH deficiency was associated with changes in lymphocyte subsets and impaired unstimulated and stimulated natural killer cell activity, but these remained abnormal during 18 months of GH replacement therapy. Extra-pituitary GH gene expression in, e.g. lymphoid tissues may serve as an autocrine/paracrine factor in immunomodulation and explain the clinical normal immune function in adult GH-deficient patients.

AB - OBJECTIVE: The aim of the present study was to investigate natural killer (NK) cell function and lymphocyte subsets in GH-deficient (GHD) adults, before and during long-term GH treatment.STUDY DESIGN: We investigated immune function in 19 adults with severe GHD, before and during 18 months of randomized treatment with GH or placebo. Measurement of lymphocyte subsets and NK cell activity was performed. Data obtained from 110 healthy adults served as reference values.RESULTS: NK cell activity, both unstimulated and stimulated by interferon-a or interleukin-2, was significantly impaired in GHD patients. Similarly, NK cell concentration and the proportion of NK cells (CD16+) were reduced in GHD patients compared to controls. Both total and proportional CD4 + cells were increased in patients compared with controls. IGF-I increased significantly during treatment, but the immune functions investigated were unaltered.CONCLUSIONS: GH deficiency was associated with changes in lymphocyte subsets and impaired unstimulated and stimulated natural killer cell activity, but these remained abnormal during 18 months of GH replacement therapy. Extra-pituitary GH gene expression in, e.g. lymphoid tissues may serve as an autocrine/paracrine factor in immunomodulation and explain the clinical normal immune function in adult GH-deficient patients.

KW - Adult

KW - Case-Control Studies

KW - Double-Blind Method

KW - Female

KW - Growth Hormone

KW - Humans

KW - Hydrocortisone

KW - Insulin-Like Growth Factor I

KW - Interferon-alpha

KW - Interleukin-2

KW - Killer Cells, Natural

KW - Lymphocyte Activation

KW - Lymphocyte Subsets

KW - Male

KW - Middle Aged

KW - Statistics, Nonparametric

KW - Thyroxine

KW - Clinical Trial

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

M3 - Journal article

C2 - 12460329

SN - 0300-0664

VL - 57

SP - 787

EP - 792

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - 6

ER -